SCHEMBL2839284

SCHEMBL2839284

NC(c1ccc(Cl)cc1)C(O)c1ccc(-c2cccnc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
MKNK1 Q9BUB5 5/20 0.45
MKNK2 Q9HBH9 5/20 0.45
CYP2A6 P11509 3/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
NPY5R Q15761 2/20 0.43
CYP17A1 P05093 1/20 0.42
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
MTOR P42345 1/20 0.41
PIK3CG P48736 1/20 0.41
PRKDC P78527 1/20 0.41
ATM Q13315 1/20 0.41
ATR Q13535 1/20 0.41
CNR1 P21554 1/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7803951 1.00 CYP19A1 (0.46) CYP19A1NPC1RAB9AMKNK1MKNK2
Hydrochloric Acid SCHEMBL2838936 0.99 CYP19A1 (0.45) CYP19A1NPC1RAB9AMKNK1MKNK2
SCHEMBL7804180 0.85 KDR (0.50) NPC1RAB9AMKNK1MKNK2CYP2A6
SCHEMBL2838945 0.85 KDR (0.50) NPC1RAB9AMKNK1MKNK2CYP2A6
SCHEMBL7809471 0.84 CYP19A1 (0.46) CYP19A1CYP3A4ATMCNR1
SCHEMBL2834054 0.84 CYP19A1 (0.46) CYP19A1CYP3A4ATMCNR1
SCHEMBL2834231 0.83 AKT1 (0.50) CYP19A1RAB9ACYP3A4CYP17A1
SCHEMBL7809316 0.83 AKT1 (0.50) CYP19A1RAB9ACYP3A4CYP17A1
SCHEMBL2840093 0.82 KCNA5 (0.42) MKNK1MKNK2CYP2A6CYP3A4
SCHEMBL7813869 0.82 KCNA5 (0.42) MKNK1MKNK2CYP2A6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 CYP19A1 1427/4885NPC1 182/4885RAB9A 2034/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 CYP19A1 1427/4885NPC1 182/4885RAB9A 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.